CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
RedFin's Chen Zhao joins Cheddar to breakdown the current state of the housing market in the United States and what prospective homebuyers need to know. Watch!
That's what his former Commerce secretary says in this interview. Plus: IRS audits, TV news ratings, nasty insults, Minecraft, Prada, and the Panama Canal.
Jeremy Jansen, Head of Global Supply Chain and Trade Sales at Wells Fargo, helps us understand how trade will be affected by tariffs implemented by Trump.
